1. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:498–505.
2. The Japan Glaucoma Society Guidelines for Glaucoma (4th edition). Nippon Ganka Gakkai Zasshi. 2018;122:5–53. (in Japanese).
3. Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18:238–43.
4. Aihara M, Sekiya T. Phase III study to evaluate the efficacy and safety of novel brimonidine/brinzolamide ophthalmic suspension compared with brinzolamide ophthalmic suspension in patients with primary open-angle glaucoma (broad-definition) or ocular hypertension. Atarashii Ganka. 2020;37:1299–308. (in Japanese).
5. Aihara M, Sekiya T. Phase III study to evaluate the efficacy and safety of novel brimonidine/brinzolamide ophthalmic suspension compared with brimonidine ophthalmic solution in patients with primary open-angle glaucoma (broad-definition) or ocular hypertension. Atarashii Ganka. 2020;37:1289–98. (in Japanese).